Comparative Pharmacology
Head-to-head clinical analysis: QVAR 80 versus SECREFLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QVAR 80 versus SECREFLO.
QVAR 80 vs SECREFLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beclomethasone dipropionate is a corticosteroid that exhibits anti-inflammatory activity. It binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators such as cytokines, chemokines, and arachidonic acid metabolites. It also reduces edema and mucus production in the airways.
SecReFlo is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity by inhibiting presynaptic serotonin reuptake.
80 mcg orally via oral inhalation twice daily (maximum 320 mcg twice daily)
One inhalation (200 mcg albuterol sulfate/80 mcg ipratropium bromide) orally 4 times daily via metered-dose inhaler. May increase to 2 inhalations 4 times daily if needed.
None Documented
None Documented
Terminal elimination half-life is approximately 2.9 hours after inhalation. This short half-life supports twice-daily dosing but does not fully reflect pulmonary residence time.
Terminal elimination half-life is 2.5 hours in patients with normal renal function. In moderate renal impairment (CrCl 30-50 mL/min), half-life increases to 4.5 hours; in severe impairment (<30 mL/min), half-life is 8 hours, requiring dosage adjustment.
Primarily hepatic metabolism, with metabolites excreted in feces (60-70%) and urine (30-40%). Less than 1% of unchanged drug is excreted in urine.
Renal: 75% as unchanged drug; fecal: 20%; biliary: 5%. Total clearance is 0.8 L/h/kg, with renal clearance accounting for 0.6 L/h/kg, indicating active tubular secretion.
Category C
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid/Long-acting Beta Agonist